A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2118 participants.
Also called NCT01018173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,118 participants
- Sponsor
- Registry
-
NCT01018173
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Brazil, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, India, Israel, Lithuania, Malaysia, Mexico, Poland, Romania, Russia, Slovakia, South Africa, Spain, Taiwan, Thailand, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01018173. Randomized; double masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- placebo
- Intervention (Drug)
- taspoglutide
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01018173- Content hash
2cc7965c34c3ec445f6f53a2be3ea52d4181349ce1336503b671f0f91b14dbf4